Navigation Links
AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community
Date:11/9/2010

WASHINGTON, Nov. 9, 2010 /PRNewswire/ -- The clinical practice guideline recently issued by the American Academy of Orthopaedic Surgeons (AAOS) for treating spinal compression fractures has left the medical community scratching its head about what to tell patients. Spinal compression fractures (also called vertebral compression fractures or VCFS) are the most common complication of osteoporosis, a disease that affects an estimated 44 million Americans, or 55 percent of adults age 50 and older. Approximately 700,000 new VCFs occur annually. They cause intractable pain and are a source of increased morbidity.

Of the 11 recommendations made by AAOS, more than half are rated as "inconclusive." According to AAOS, evidence quality was critical in supporting the practice guidelines and it didn't find enough high-quality evidence to support or oppose most non-surgical treatments, including traditional treatment options such as bed rest, analgesics, bracing, and physical therapy.

AAOS made only one "strong" recommendation. It was against the use of vertebroplasty, a minimally invasive procedure that involves injecting bone cement into the fracture to

stabilize and strengthen the vertebra. The group based its recommendation on the results of two studies published in the New England Journal of Medicine (NEJM). The studies compared vertebroplasty against a placebo procedure and found no statistically significant difference between the two.

But did the studies exhibit enough clinically efficiency to justify that recommendation? "No," says Dr. Wayne Olan, MD, Director of Interventional and Endovascular Neurosurgery at George Washington University Medical Faculty Associates in Washington, DC, and a consulting physician for neuroradiology at the National Institutes of Health in Bethesda, Md.

"The NEJM studies don't come close to the standards AAOS set for its guideline. Their methodology is flawed and their conclusions are at odds with more than 20 years of research studies that substantiate the efficacy of vertebroplasty."

Numerous commentaries from medical experts agree with Dr. Olan. They criticize Kallmes et al and Buchbinder et al for including patients with sub-acute and chronic fractures up to a year old, inconsistent use of the evidence of bone edema on MRI as an inclusion criteria, selection bias, statistical power of the sample size, the absence of a control group that did not get an intervention, and the high crossover from placebo to vertebroplasty.

A more rigorous study, says Dr. Olan, is "Vertebroplasty vs. Conservative Treatment in Osteoporotic Vertebral Compression Fractures" (VERTOS II), published recently in The Lancet.

VERTOS II is the largest, peer-reviewed study of vertebroplasty to date. In it, 202 patients with acute fractures confirmed by edema on MRI were randomly allocated to receive either vertebroplasty or conservative medical therapy. Patients receiving vertebroplasty had greater pain relief – as measured on a visual analog scale (VAS) – from the first day after the procedure to one year later than those treated conventionally. From baseline, the reductions in pain were 5.2 at 1 month and 5.7 at 1 year. Pain reductions in the control group were less substantial at 2.7 at 1 month and 3.7 at 1 year.

"Randomized, placebo-controlled trials provide only an approximation of the truth. Information from observational outcome studies is also important because patients and physicians in the real world don't always behave like those in clinical trials," says Dr. Olan.

"As physicians we need to weigh study results against our own experience. VERTOS II and the countless patients I've treated who have benefitted from vertebroplasty validate this procedure's efficacy."

In addition to his practice, Dr. Olan is clinical associate professor of radiology and neurological surgery at The George Washington University Medical Center in Washington, DC. He has participated in multiple clinical trials and published extensively on minimally invasive spinal interventions. He is also a frequent lecturer and instructor around the world regarding minimally invasive spinal techniques.

Disclosures:

Dr. Olan is a consultant with Stryker Interventional Spine and conducts vertebroplasty workshops supported by the company.


'/>"/>
SOURCE Wayne J. Olan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):